Showing 181 - 200 results of 295 for search '"Knight Cancer Institute"', query time: 0.38s Refine Results
  1. 181
  2. 182

    Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date by Fletcher L, Joshi SK, Traer E

    Published 2020-01-01
    “…Luke Fletcher,1,2 Sunil K Joshi,1–3 Elie Traer1,2 1Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA; 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; 3School of Medicine, Oregon Health & Science University, Portland, OR 97239, USACorrespondence: Elie TraerOregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code: KR-HEM, Portland, OR 97239, USATel +1 503 494 3553Fax +1 503 494 3465Email traere@ohsu.eduAbstract: Acute myeloid leukemia (AML) is a clonal hematologic neoplasm characterized by rapid, uncontrolled cell growth of immature myeloid cells (blasts). …”
    Get full text
    Article
  3. 183
  4. 184

    Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives by Luo J, Graff JN

    Published 2016-11-01
    “…Jia Luo,1 Julie N Graff2,3 1Department of Medicine; 2Knight Cancer Institute, Oregon Health & Science University, 3VA Portland Health Care System, Portland, OR, USA Abstract: Prostate cancer claims the lives of more than 25,000 men in the United States yearly, most from metastatic disease. …”
    Get full text
    Article
  5. 185
  6. 186
  7. 187
  8. 188
  9. 189
  10. 190
  11. 191
  12. 192
  13. 193
  14. 194
  15. 195
  16. 196
  17. 197
  18. 198
  19. 199
  20. 200